Posts

Newly public biotechs are having a strong—but uneven—2026

on

Amgen reports promising Phase 2 results for skin-focused lupus antibody

on

Lilly’s amylin–Zepbound combination shows stronger weight loss in mid-stage trial

on

Pierre Fabre refiles tabelecleucel after agreeing on an FDA path forward

on

Varda raises $250 million to scale orbital drug manufacturing

on

BioNTech to close three German sites after sale efforts fail

on

EQT Foundation backs 11 brain drug-delivery research projects

on

Biosimilars emerge as a potential next direct-to-employer drug strategy

on

UniQure slides as four-year Huntington’s data show a weaker, statistically uncertain benefit

on

PhRMA names Eric Cantor as next chief

on

ai3Bio launches with $48M to target disease-driving immune cells

on

AstraZeneca invests $2 billion in Summit to advance ivonescimab–ADC combinations

on

Novo licenses Hengrui’s early-stage oral obesity candidate in potential $2.6B deal

on

U.S. details 0% tariff rules for specialty medicines

on

Merck licenses SciBrunch’s preclinical KRAS drug in deal worth up to $2.13B

on

Roche drops emugrobart obesity program and returns rights to Chugai

on

Mirum’s brelovitug meets Phase 3 primary endpoint in hepatitis delta

on

BARDA offers SCYNEXIS up to $214 million for antifungal SCY-247

on

Could bundled digital and IVD testing speed Alzheimer’s trial referrals?

on

Arvinas doses first patient in ARV-6723 Phase 1/2 trial

on

Biomanufacturing after COVID: keeping emergency readiness commercially viable

on

Kodiak stock surges after two eye-drug candidates match Eylea in Phase 3

on

Merck licenses SciBrunch’s preclinical KRAS G12D drug in deal worth up to $2.13B

on

Merck and Daiichi withdraw lung-cancer drug filing after FDA pushback

on

Adicet reports encouraging early lupus CAR-T data as shares fall

on

ctDNA clearance: a promising early signal, not yet a definitive endpoint

on

Nektar wins $90 million jury award in dispute with Eli Lilly

on